(R)-(3-Amino-2-fluoropropyl) Phosphinic Acid (AZD3355), a Novel GABAB Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxation through a Peripheral Mode of Action
Anders Lehmann(Novartis (Switzerland)), Sverker von Unge, Simo S. Oja(Tampere University Hospital), John Dent(Royal Adelaide Hospital), Lena Brändén, Britt-Marie Jacobson, Thomas Elebring(AstraZeneca (Sweden)), Amanda J. Page(Hanson Institute), Jan P. Mattsson(Novartis (Switzerland)), Madeleine Antonsson, Hans Bräuner‐Osborne(University of Copenhagen), Karolina Nilsson, Jörgen Jensen, Ann Aurell Holmberg, Pirjo Saransaari, B. C. Christiansen(University of Copenhagen), L. Ashley Blackshaw(Royal Adelaide Hospital)
Cited by 55
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Healing and relapse of severe peptic esophagitis after treatment with omeprazole
|Gastroenterology|1988|786
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa
|Gastroenterology|2000|544
Ligands for Glutamate Receptors: Design and Therapeutic Prospects
|Journal of Medicinal Chemistry|2000|525
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488